In addition, subgroup analysis of early-stage data from 430 subjects from eight studies also demonstrated that low expression of p16 significantly affected RFS in patients with early-stage (Ta–T1) bladder cancer (HR = 1.96, 95% CI = 1.23~3.14, and P = 0.005; I2 = 47.9%, P = 0.088). Here, CDKN2A is linked to urinary bladder cancer.